A new study by the International Agency for Research on Cancer (IARC), in partnership with Costa Rican investigators and the National Cancer Institute (NCI), shows for the first time that the vaccine against human papillomavirus (HPV) types 16 and 18, which is used to prevent cervical cancer, also...
Oncologists now have a new prognostic tool to help determine the risk of recurrence in patients with carcinoma of the major salivary glands and may help guide their post-treatment surveillance, according to study results published in JAMA Otolaryngology–Head & Neck Surgery. Researchers...
Previous studies have shown that anti-EGFR monoclonal antibody treatment can improve clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. In the open-label phase III SPECTRUM trial, Jan B. Vermorken, MD, of Antwerp University Hospital and...
Smokers and single men are more likely to acquire oncogenic oral human papillomavirus (HPV), according to new results from the HPV Infection in Men (HIM) Study. Researchers from Moffitt Cancer Center, the National Cancer Institute, Mexico, and Brazil also reported that newly acquired oral HPV...
The rapid increase in papillary thyroid cancer in the United States may not be linked to increase in occurrence, but instead may be linked to an increase in the diagnosis of precancerous conditions and to a person's insurance status, according to a study published online in Thyroid. "This [study]...
Researchers have found that antibodies against the human papillomavirus (HPV) may help identify individuals who are at greatly increased risk of HPV-related cancer of the oropharynx, In their study, at least one in three individuals with oropharyngeal cancer had antibodies to HPV, compared to...
A randomized phase III study found that the targeted drug sorafenib (Nexavar) stalls disease progression by 5 months in patients with metastatic differentiated thyroid cancer that has progressed despite standard radioactive iodine therapy. If approved in this setting by the U.S. Food and Drug...
Spouses and long-term partners of patients diagnosed with human papillomavirus (HPV)-positive oropharyngeal cancer were no more likely to test positive for oral HPV infection than people in the general population and have a low risk of HPV-related oropharyngeal cancer, according to the Human Oral...
The FDA has granted fast track designation to the SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in patients with head and neck cancer. SGX942 is a fully synthetic, 5-amino acid peptide with high aqueous solubility and...
Frequent heartburn was positively associated with cancers of the throat and vocal cord among nonsmokers and nondrinkers, and the use of antacids, but not prescription medications, had a protective effect, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of...
A new measure of the heterogeneity of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue of the journal Cancer, investigators at Massachusetts General Hospital (MGH) and Massachusetts Eye and Ear...
More than a quarter of a century after the Chernobyl nuclear disaster, many children and teenagers who developed thyroid cancer due to radiation are in complete or near remission, according to a recent study accepted for publication in The Endocrine Society’s Journal of Clinical Endocrinology ...
A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, said researchers at Mayo Clinic in Florida. Anaplastic thyroid cancer is one of the deadliest of all cancers. Nearly all patients diagnosed...
Researchers at Roswell Park Cancer Institute (RPCI) have found that a new formulation of a promising anticancer agent, the small chemical molecule FL118, is even more effective in controlling two types of cancer than a version reported in PLOS ONE 6 months earlier proved to be. Additional evidence...
A study of older patients with advanced head and neck cancers has found that where they were treated significantly influenced their survival. The study, led by researchers at Fred Hutchinson Cancer Research Center and published in the March 1 online edition of Cancer, found that patients who...
A new drug combination shows promise in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck. The results of the study, which included preclinical and clinical analyses, were published in Clinical Cancer Research, a journal...
The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine, the most effective therapy for the disease, according to new research from Memorial Sloan-Kettering Cancer Center. Published in the February 14 issue of the New England...